Publications by authors named "James List"

Claim this Profile
N
New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
Hiddo J L Heerspink, James List, Vlado Perkovic

Diabetes Obes Metab· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List

Metabolism· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
C David Sjöström, Peter Johansson, Agata Ptaszynska, James List, Eva Johnsson

Diab Vasc Dis Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, James List

Diabetes Care· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The authors reply.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List

Kidney Int· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Agata Ptaszynska, Kristina M Johnsson, Shamik J Parikh, Tjerk W A de Bruin, Anne Marie Apanovitch, James F List

Drug Saf· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh, James F List

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary tract infections in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh, James F List

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List

Kidney Int· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Sunder Mudaliar, Robert R Henry, Guenther Boden, Steven Smith, Alexandros-Georgios Chalamandaris, James List

Diabetes Technol Ther· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh

Diabetes Res Clin Pract· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, James F List

Clin Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on cardiovascular risk factors.
Agata Ptaszynska, Elise Hardy, Eva Johnsson, Shamik Parikh, James List

Postgrad Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List

BMC Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
Jean M Whaley, Mark Tirmenstein, Timothy P Reilly, Simon M Poucher, Joanne Saye, James F List

Diabetes Metab Syndr Obes· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Julio Rosenstock, Marisa Vico, Li Wei, Afshin Salsali, James F List

Diabetes Care· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Serge A Jabbour, Jean M Whaley, Mark Tirmenstein, Simon M Poucher, Timothy P Reilly, James F List

Postgrad Med· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.
Antonio R Chacra, Gerry H Tan, Shoba Ravichandran, James List, Roland Chen

Diab Vasc Dis Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
James F List, Jean M Whaley

Kidney Int Suppl· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List

Diabetes Care· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition.
Liping Zhang, Chee M Ng, James F List, Marc Pfister

J Clin Pharmacol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List

Lancet· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
John P H Wilding, Paul Norwood, Caroline T'joen, Arnaud Bastien, James F List

Diabetes Care· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek

Diabetes Care· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin.
James F List, Huile He, Joel F Habener

Regul Pept· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis